MGTA Annual CFO
-$67.09 M
-$7.56 M-12.70%
31 December 2022
Summary:
As of January 21, 2025, MGTA annual cash flow from operations is -$67.09 million, with the most recent change of -$7.56 million (-12.70%) on December 31, 2022. During the last 3 years, it has fallen by -$9.99 million (-17.49%).MGTA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MGTA Quarterly CFO
-$6.54 M
+$29.05 M+81.62%
30 June 2023
Summary:
As of January 21, 2025, MGTA quarterly cash flow from operations is -$6.54 million, with the most recent change of +$29.05 million (+81.62%) on June 30, 2023. Over the past year, it has increased by +$10.31 million (+61.17%).MGTA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MGTA TTM CFO
-$72.64 M
+$10.31 M+12.43%
30 June 2023
Summary:
As of January 21, 2025, MGTA TTM cash flow from operations is -$72.64 million, with the most recent change of +$10.31 million (+12.43%) on June 30, 2023. Over the past year, it has dropped by -$6.29 million (-9.48%).MGTA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MGTA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -12.7% | +61.2% | -9.5% |
| 3 y3 years | -17.5% | +65.9% | -15.3% |
| 5 y5 years | -201.3% | +28.2% | -27.2% |
MGTA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | ||||||
| 5 y | 5-year | ||||||
| alltime | all time | +927.6% | +62.4% | +1702.5% |
Magenta Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2023 | - | -$6.54 M(-81.6%) | -$72.64 M(-12.4%) |
| Mar 2023 | - | -$35.60 M(+113.3%) | -$82.95 M(+23.6%) |
| Dec 2022 | -$67.09 M(+12.7%) | -$16.69 M(+20.9%) | -$67.09 M(+1.5%) |
| Sept 2022 | - | -$13.81 M(-18.1%) | -$66.09 M(-0.4%) |
| June 2022 | - | -$16.85 M(-14.6%) | -$66.35 M(+6.2%) |
| Mar 2022 | - | -$19.74 M(+25.8%) | -$62.50 M(+5.0%) |
| Dec 2021 | -$59.53 M(-7.0%) | -$15.69 M(+11.5%) | -$59.53 M(+3.4%) |
| Sept 2021 | - | -$14.07 M(+8.2%) | -$57.57 M(-0.6%) |
| June 2021 | - | -$13.00 M(-22.5%) | -$57.94 M(-9.7%) |
| Mar 2021 | - | -$16.77 M(+22.1%) | -$64.14 M(+0.2%) |
| Dec 2020 | -$64.02 M | -$13.73 M(-4.8%) | -$64.02 M(-2.9%) |
| Sept 2020 | - | -$14.43 M(-24.9%) | -$65.92 M(+4.6%) |
| June 2020 | - | -$19.20 M(+15.3%) | -$63.00 M(+7.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$16.66 M(+6.6%) | -$58.82 M(+3.0%) |
| Dec 2019 | -$57.10 M(+36.3%) | -$15.63 M(+35.8%) | -$57.10 M(+5.6%) |
| Sept 2019 | - | -$11.51 M(-23.5%) | -$54.10 M(+1.8%) |
| June 2019 | - | -$15.03 M(+0.6%) | -$53.14 M(+12.5%) |
| Mar 2019 | - | -$14.94 M(+18.3%) | -$47.22 M(+12.7%) |
| Dec 2018 | -$41.89 M(+88.1%) | -$12.62 M(+19.7%) | -$41.89 M(+11.7%) |
| Sept 2018 | - | -$10.55 M(+15.8%) | -$37.49 M(+15.8%) |
| June 2018 | - | -$9.11 M(-5.2%) | -$32.39 M(+16.3%) |
| Mar 2018 | - | -$9.60 M(+16.7%) | -$27.84 M(+25.0%) |
| Dec 2017 | -$22.26 M(+241.0%) | -$8.23 M(+51.2%) | -$22.26 M(+58.7%) |
| Sept 2017 | - | -$5.44 M(+19.4%) | -$14.03 M(+63.4%) |
| June 2017 | - | -$4.56 M(+13.1%) | -$8.59 M(+113.1%) |
| Mar 2017 | - | -$4.03 M | -$4.03 M |
| Dec 2016 | -$6.53 M | - | - |
FAQ
- What is Magenta Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Magenta Therapeutics?
- What is Magenta Therapeutics annual CFO year-on-year change?
- What is Magenta Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Magenta Therapeutics?
- What is Magenta Therapeutics quarterly CFO year-on-year change?
- What is Magenta Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Magenta Therapeutics?
- What is Magenta Therapeutics TTM CFO year-on-year change?
What is Magenta Therapeutics annual cash flow from operations?
The current annual CFO of MGTA is -$67.09 M
What is the all time high annual CFO for Magenta Therapeutics?
Magenta Therapeutics all-time high annual cash flow from operations is -$6.53 M
What is Magenta Therapeutics annual CFO year-on-year change?
Over the past year, MGTA annual cash flow from operations has changed by -$7.56 M (-12.70%)
What is Magenta Therapeutics quarterly cash flow from operations?
The current quarterly CFO of MGTA is -$6.54 M
What is the all time high quarterly CFO for Magenta Therapeutics?
Magenta Therapeutics all-time high quarterly cash flow from operations is -$4.03 M
What is Magenta Therapeutics quarterly CFO year-on-year change?
Over the past year, MGTA quarterly cash flow from operations has changed by +$10.31 M (+61.17%)
What is Magenta Therapeutics TTM cash flow from operations?
The current TTM CFO of MGTA is -$72.64 M
What is the all time high TTM CFO for Magenta Therapeutics?
Magenta Therapeutics all-time high TTM cash flow from operations is -$4.03 M
What is Magenta Therapeutics TTM CFO year-on-year change?
Over the past year, MGTA TTM cash flow from operations has changed by -$6.29 M (-9.48%)